Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 12/20 | 0.51 |
| ▸ | NPY1R | P25929 | 7/20 | 0.51 |
| ▸ | NPY2R | P49146 | 5/20 | 0.51 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.51 |
| ▸ | FURIN | P09958 | 5/20 | 0.42 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.42 |
| ▸ | CTSD | P07339 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30339863 | 1.00 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RFURIN | |
| SCHEMBL30456880 | 1.00 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RFURIN | |
| SCHEMBL29732335 | 1.00 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RFURIN | |
| SCHEMBL30305367 | 1.00 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RFURIN | |
| SCHEMBL30148454 | 1.00 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RFURIN | |
| SCHEMBL30945400 | 1.00 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RFURIN | |
| SCHEMBL29799775 | 1.00 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RFURIN | |
| SCHEMBL30945410 | 1.00 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RFURIN | |
| SCHEMBL1527410 | 1.00 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RFURIN | |
| SCHEMBL30305284 | 1.00 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RFURIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282838-A1 | Multi-Epitope Vaccine for the Treatment of Alzheimer's Disease | OTHAIR PROTHENA LIMITED (IE) | 2025-09-11 | — | — | US | claimed |
| US-20250186567-A1 | MULTIEPITOPE VACCINE FOR THE TREATMENT OF ALZHEIMER'S DISEASE | OTHAIR PROTHENA LTD (IE) | 2025-06-12 | — | — | US | claimed |
| US-12247056-B2 | Multi-epitope vaccine for the treatment of Alzheimer's disease | OTHAIR PROTHENA LIMITED (IE) | 2025-03-11 | — | — | US | claimed |
| US-20240343769-A1 | Multi-Epitope Vaccine for the Treatment of Alzheimer's Disease | OTHAIR PROTHENA LIMITED (IE) | 2024-10-17 | — | — | US | claimed |
| US-11965005-B2 | Multi-epitope vaccine for the treatment of Alzheimer's disease | OTHAIR PROTHENA LIMITED (IE) | 2024-04-23 | — | — | US | claimed |
| US-11952406-B2 | Multi-epitope vaccine for the treatment of Alzheimer's disease | OTHAIR PROTHENA LIMITED (IE) | 2024-04-09 | — | — | US | claimed |
| US-11945849-B2 | Multi-epitope vaccine for the treatment of Alzheimer's disease | OTHAIR PROTHENA LIMITED (IE) | 2024-04-02 | — | — | US | claimed |
| US-20230355729-A1 | MULTIEPITOPE VACCINE FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BARBOUR ROBIN (US) | 2023-11-09 | — | — | US | claimed |
| US-20230322876-A1 | Multi-Epitope Vaccine for the Treatment of Alzheimer's Disease | OTHAIR PROTHENA LIMITED (IE) | 2023-10-12 | — | — | US | claimed |
| US-20230312662-A1 | Multi-Epitope Vaccine for the Treatment of Alzheimer's Disease | OTHAIR PROTHENA LIMITED (IE) | 2023-10-05 | — | — | US | claimed |
| US-20230295254-A1 | Multi-Epitope Vaccine for the Treatment of Alzheimer's Disease | OTHAIR PROTHENA LIMITED (IE) | 2023-09-21 | — | — | US | claimed |
| EP-4213941-A1 | MULTIEPITOPE VACCINE FOR THE TREATMENT OF ALZHEIMER'S DISEASE | OTHAIR PROTHENA LIMITED (IE) | 2023-07-26 | — | — | EP | claimed |
| CN-116472055-A | Multi-epitope vaccine for treating Alzheimer's disease | 欧萨尔普罗席纳有限公司 | 2023-07-21 | — | — | CN | claimed |
| CN-116438191-A | Multi-epitope vaccine for treating Alzheimer's disease | 欧萨尔普罗席纳有限公司 | 2023-07-14 | — | — | CN | claimed |
| US-20230183304-A1 | Multi-Epitope Vaccine for the Treatment of Alzheimer's Disease | PROTHENA BIOSCIENCES INC | 2023-06-15 | — | — | US | claimed |
| EP-4192497-A1 | MULTIEPITOPE VACCINE FOR THE TREATMENT OF ALZHEIMER'S DISEASE | OTHAIR PROTHENA LIMITED (IE) | 2023-06-14 | — | — | EP | claimed |
| CN-115867304-A | Multi-epitope vaccine for treating alzheimer's disease | 欧萨尔普罗席纳有限公司 | 2023-03-28 | — | — | CN | claimed |
| WO-2022060488-A1 | MULTIEPITOPE VACCINE FOR THE TREATMENT OF ALZHEIMER'S DISEASE | OTHAIR PROTHENA LIMITED (IE) | 2022-03-24 | — | — | WO | claimed |
| WO-2026106695-A1 | TARGETED NANOPARTICLES ENCAPSULATING WATER-SOLUBLE THERAPEUTICS, METHODS OF PRODUCTION, AND USE | OPTIMEOS LIFE SCIENCES, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| WO-2004009113-A1 | USE OF CONVERTASE INHIBITORS IN THE TREATMENT OF FIBROSIS AND SCARRING | RENOVO LIMITED (GB) | 2004-01-29 | — | — | WO | disclosed |